Document:

EX-10.24

 Exhibit 10.24 

BAUSCH HEALTH COMPANIES INC. 

2150 St. Elzéar Blvd. West 

Laval, Québec, Canada H7L 4A8 

March 30, 2022 
 Bausch + Lomb Corporation

 400 Somerset Corporate Blvd 
 Bridgewater, NJ 08807, USA 

Attention: General Counsel 
 Solta Medical Corporation 

520 Applewood Crescent 
 Vaughan, Ontario, Canada L4K 5X3 

Attention: General Counsel 
 Re: Potential Separation of Solta
Medical 
 Reference is made to (i) Master Separation Agreement, dated as of March 30, 2022 (as it may be modified in
accordance with its terms, the “B+L MSA”), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia, Canada (“BHC”), and Bausch + Lomb Corporation, a
company incorporated under the laws of Canada (“B+L”), and (ii) the draft form of Master Separation Agreement (as it may be modified, the “Solta MSA”), by and between Bausch Health Companies Inc., a
corporation continued under the laws of the Province of British Columbia, Canada (“BHC”), and Solta Medical Corporation, a corporation incorporated under the British Columbia Business Corporation Act (“Solta”). 

As the parties hereto are aware, BHC has previously announced its intention to (i) separate its global aesthetic medical device business
(the “Solta Business”) from its other businesses and (ii) separate its global eye health products business (the “B+L Business”) from its other businesses. In the event BHC enters into definitive documentation
with respect to any transaction or series of transactions pursuant to which it effectuates the separation by way of an initial public offering, listing, spin off, split off or any other similar transaction (or combination of any of the foregoing) of
the entities that hold the Solta Business (such entities, the “Solta Entities”), then, prior to or concurrently with the entry into such documentation, Solta (or applicable subsidiaries thereof) shall enter into the B+L MSA and/or
any applicable Ancillary Agreements (as defined in the B+L MSA), including the Transition Services Agreement (as defined in the B+L MSA) with respect to the rights and obligations of BHC thereunder applicable to the Solta Entities or
the Solta Business such that any such rights and obligations shall become rights and obligations directly between Solta (or other Solta Entities) and B+L (or other B+L Entities). In addition, the parties will discuss, in good faith and acting
reasonably, whether B+L (or other entities that hold the B+L Business (such entities, together with B+L, the “B+L Entities”) should enter into the Solta MSA and/or any applicable Ancillary Agreements (as defined in the Solta
MSA) such that any rights and obligations of BHC and Solta thereunder, to the extent the more appropriate counterparty with Solta is B+L (or another B+L Entity, as applicable) shall become rights and obligations directly between Solta
(or other Solta Entities) and B+L (or other B+L Entities). In such event, the parties will negotiate appropriate modifications to the B+L MSA, the Solta MSA, and/or any applicable Ancillary Agreements, if necessary, in good faith for the purpose of
causing the applicable entities to be so bound. 
 This letter agreement will be governed by and construed in accordance with the laws of
the State of Delaware without giving effect to conflict of laws principles that would result in the application of the law of any other state. Sections 11.2 (Governing Law), 11.4 (Third-Party Beneficiaries), 11.5 (Notices),

 
11.6 (Severability), 11.10 (Headings), 11.13 (Specific Performance), 11.14 (Amendments) and 11.18 (Mutual Drafting) of the B+L MSA are hereby incorporated
herein by reference, mutatis mutandis. This letter agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the
same agreement. This letter agreement may be executed and delivered by facsimile or PDF and upon such delivery, a copy of the signature will be deemed to have the same effect as if the original signature had been delivered to the other parties. 

If the foregoing accurately memorializes an agreement to the matters described above, please sign below. 

[Signature page follows] 

  
 -2- 

 
					
	Agreed and acknowledged as of
	the date first written above:
	
	BAUSCH HEALTH COMPANIES INC.
		
	By:	 	 /s/ Thomas J. Appio

		 	Name: Thomas J. Appio
		 	Title: Chief Executive Officer, Pharma Business

  

			
	 Agreed and acknowledged as of

	the date first written above:
	
	BAUSCH + LOMB CORPORATION
		
	By:	 	 /s/ Joseph C. Papa

		 	Name: Joseph C. Papa
		 	Title: Chief Executive Officer
	
	Agreed and acknowledged as of
	the date first written above:
	
	SOLTA MEDICAL CORPORATION
		
	By:	 	 /s/ Judah Bareli

		 	Name: Judah Bareli
		 	Title: General Counsel

 [Signature Page to Solta Side Letter]EX-10.25

 Exhibit 10.25 

REDACTED 
 Certain
identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. 

DIRECTOR APPOINTMENT AND NOMINATION AGREEMENT 

This Director Appointment and Nomination Agreement, dated as of April 28, 2022 (this “Agreement”), is by and among the
persons and entities listed on Schedule A (collectively, the “Icahn Group”, and each individually a “member” of the Icahn Group) and Bausch + Lomb Corporation (the “Company”). In consideration of
and reliance upon the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

 

	1.	 Board Representation and Board Matters. 

 

	 	(a)	 The Company and the Icahn Group agree as follows: 

 

	 	(i)	 As soon as practicable following the written election of the Icahn Group (which written election, in order to
be valid, must be delivered to the Company between the date (the “Distribution Effective Date”) of consummation of the spin-off transaction by which Bausch Health Companies Inc.
(“BHC”) transfers any or all of its remaining indirect equity interest in the Company to BHC’s then-current shareholders (the “B+L Distribution”) and such date that is twelve (12) months after the
Distribution Effective Date (such period, the “Election Period”), the Company shall take or shall have taken all necessary action to increase the size of the Board of Directors of the Company (the “Board”) by two,
and following consultation with the Icahn Group, to appoint two individuals identified by the Icahn Group and reasonably acceptable to the Company (such individuals, collectively, the “Icahn Designees” and each an “Icahn
Designee”) to fill the resulting vacancies, each with a term expiring at the first annual general meeting of stockholders of the Company following such written election (the “First Annual Meeting”). Prior to such date as
the Icahn Designees are seated as members of the Board, the Icahn Group shall not request and the Company shall not provide any material non-public information relating to or involving the Company. For the
avoidance of doubt, it shall not be deemed unreasonable for the Company to reject a designee in accordance with this Section 1(a)(i) if such designee does not satisfy the Director Criteria (as hereafter defined) or the
criteria set forth on Annex 1 attached hereto (the “Tax Criteria”). 

  

	 	(ii)	 the Company shall use reasonable best efforts to cause the election of each of the Icahn Designees at the First
Annual Meeting (including by (x) recommending that the Company’s stockholders vote in favor of the election of each of the Icahn Designees, (y) including each of the Icahn Designees in the Company’s proxy statement and proxy card
for the First Annual Meeting, and (z) otherwise supporting each of the Icahn Designees for election in a manner no less rigorous and favorable than the manner in which the Company supports its other nominees in the aggregate). The Icahn Group
agrees not to conduct a proxy contest regarding any matter, including the election of directors, with respect to the First Annual Meeting. As a condition to the Icahn Designees’ appointment to the Board, the Icahn Designees shall execute and
deliver a customary joinder to this Agreement. Prior to the execution and delivery of such joinder to the Company, the Icahn Group shall cause the Icahn Designees to comply with the covenants, agreements and other provisions herein applicable to the
Icahn Designees. 

	 	(iii)	 that as a condition to the Icahn Designees’ appointment to the Board and subsequent nomination for
election, the Icahn Designees each agree to provide to the Company, prior to nomination and appointment and on an on-going basis while serving as a member of the Board, such information and materials as the
Company routinely receives from other members of the Board or as is required to be disclosed in proxy statements under applicable law or as is otherwise reasonably requested by the Company from time-to-time from all members of the Board in connection with the Company’s legal, regulatory, auditor or stock exchange requirements, including, but not limited to, a completed D&O Questionnaire in
the form separately provided by the Company to the Icahn Group (the “Nomination Documents”). 

  

	 	(iv)	 That, subject to Section 1(c) below, should any Icahn Designee resign from the Board
or be rendered unable to, or refuse to, be appointed to, or for any other reason fail to serve or is not serving, on the Board (other than as a result of not being nominated by the Company for election at an annual meeting of stockholders subsequent
to the First Annual Meeting, following which the Icahn Group’s replacement rights pursuant to this Section 1(a)(iv) shall terminate with respect to such Icahn Designee), as long as the Icahn Group has not materially
breached this Agreement and failed to cure such breach within five (5) business days of written notice from the Company specifying any such breach, the Icahn Group shall be entitled to designate, and the Company shall cause to be added as a
member of the Board, or as a nominee on the Company’s slate of nominees for election to the Board at the First Annual Meeting (collectively, the “First BLCO Slate”), as applicable, a replacement that is approved by the Board,
such approval not to be unreasonably withheld, conditioned or delayed (an “Acceptable Person”) (and if such proposed designee is not an Acceptable Person, the Icahn Group shall be entitled to continue designating a recommended
replacement until such proposed designee is an Acceptable Person) (a “Replacement Designee”). Any such Replacement Designee who becomes a Board member in replacement of any Icahn Designee shall be deemed to be an Icahn Designee for
all purposes under this Agreement and, as a condition to being appointed to the Board, shall be required to sign a customary joinder to this Agreement. 

  

	 	(v)	 For the avoidance of doubt, the Board’s approval of a Replacement Designee pursuant to
Section 1(a)(iv) shall not be considered unreasonably withheld if: (1) such replacement does not (A) qualify as “independent” pursuant to the NYSE Rules (as defined below), (B) have the relevant
financial and business experience to be a director of the Company, or (C) satisfy the requirements set forth in the Company Policies (as defined below), in each case as in effect as of the Distribution Effective Date or such additional or
amended guidelines and policies approved by the Board that are applicable to all directors of the Company (collectively clauses (A) through (C), the “Director Criteria”); provided that no Director Criteria will be adopted that
would prevent any employee or affiliate of the Icahn Group from becoming directors by virtue of the fact that such person is an employee or affiliate of the Icahn Group had such criteria been in effect today; or (2) such Replacement Designee
does not satisfy the Tax Criteria. 

  
 2 

	 	(vi)	 that (1) for any annual general meeting of stockholders subsequent to the First Annual Meeting, the
Company shall notify the Icahn Group in writing no less than thirty-five (35) calendar days before the advance notice deadline set forth in the Company’s Articles of Incorporation whether the Icahn Designees will be nominated by the
Company for election as directors at such annual general meeting and, (2) if the Icahn Designees are to be so nominated, shall use reasonable best efforts to cause the election of the Icahn Designees so nominated by the Company (including by
(x) recommending that the Company’s stockholders vote in favor of the election of the Icahn Designees, (y) including the Icahn Designees in the Company’s proxy statement and proxy card for such annual general meeting and
(z) otherwise supporting the Icahn Designees for election in a manner no less rigorous and favorable than the manner in which the Company supports its other nominees in the aggregate), and the Icahn Group agrees not to conduct a proxy contest
regarding any matter, including the election of directors, with respect to any such annual general meeting at which the Company has nominated Icahn Designees and such Icahn Designees have consented to being named, and are named, in the proxy
statement relating to such annual general meeting. 

  

	 	(vii)	 that from and after the date of this Agreement, so long as an Icahn Designee is seated as a member of the
Board, without the approval of the Icahn Designees then on the Board (such approval not to be unreasonably withheld, delayed or conditioned), (w) the Board shall not form an Executive Committee or any other committee with functions similar to those
customarily granted to an Executive Committee; (x) the Board shall not form any other new committee (other than committees formed with respect to matters for which there are actual conflicts of interest between the Icahn Designees and the
Company) without offering to at least one Icahn Designee the opportunity to be a member of such committee (provided, however that if such committee has more than five (5) members then both Icahn Designees shall be offered to be appointed to
such committee (to the extent there are two Icahn Designees then on the Board)), (y) the Board shall not increase the size of any committee and (z) any Board consideration of appointment and employment of named executive officers, mergers and
acquisitions of material assets, or dispositions of material assets, or similar extraordinary transactions, such consideration, and voting with respect thereto shall take place only at the full Board level or in committees of which one of the Icahn
Designees is a member (for the avoidance of doubt, nothing in this Agreement changes, amends, or modifies the authority, duties and obligations of the Talent & Compensation Committee of the Board). 

 

	 	(viii)	 each of the Icahn Designees confirms that he or she will recuse himself or herself from such portions of Board
or committee meetings, if any, involving actual conflicts between the Company and the Icahn Group. Promptly following the receipt of the Nomination Documents, the Board shall make a determination as to whether the Icahn Designees, based solely upon
the representations provided by the Icahn Group in Section 7 of this Agreement (which representations shall be updated by the Icahn Group to be current as of the date of the written election made pursuant to
Section 1(a)(i)) and the information provided to the Board by the Icahn Designees in the Nomination Documents, are independent under the Board’s independence guidelines, the independence requirements of the New York
Stock Exchange (the “NYSE Rules”), and the independence standards applicable to the Company under paragraph (a)(1) of Item 407 of Regulation S-K under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). 

  
 3 

	 	(ix)	 that, to the extent permitted by law and the Company’s then-existing insurance coverage, from and after
the date that the Icahn Designees are seated as members of the Board, the Icahn Designees shall be covered by the same indemnification and insurance provisions and coverage as are applicable to the individuals that are directors of the Company as of
such time, and at such time the Icahn Designees are no longer members of the Board, then the same indemnification and insurance provisions and coverage as are applicable to former directors of the Company as of such time. 

 

	 	(i)	 Notwithstanding the foregoing, the Company acknowledges that for so long as the Icahn Designees are members of
the Board, the Icahn Designees shall have the same rights as any other director with respect to being permitted to attend (as an observer and without voting rights) any committee meeting regardless of whether such director is a member of such
committee. 

  

	 	(b)	 At all times from the date that the Icahn Designees are seated as members of the Board through the termination
of their service as a member of the Board, each of the Icahn Designees shall comply with all written policies, procedures, processes, codes, rules, standards and guidelines applicable to all non-employee Board
members and of which the Icahn Designees have been provided written copies in advance (or which have been filed with the Securities and Exchange Commission (“SEC”) or posted on the Company’s website), including the
Company’s code of business conduct, corporate policies on ethical business conduct, political contributions, lobbying and other political activities policy, conflicts of interest policy, insider trading policy, anti-hedging policy and
governance policies (collectively, the “Company Policies”), and shall preserve the confidentiality of Company business and information, including discussions or matters considered in meetings of the Board or Board committees (except
to the extent permitted in the Confidentiality Agreement (as defined below) to be entered into pursuant to Section 5 of this Agreement). In addition, each of the Icahn Designees is aware of and shall act in accordance with his or her fiduciary
duties with respect to the Company and its stockholders. For the avoidance of doubt, the Parties agree that notwithstanding the terms of any Company Policies, in no event shall any Company Policy apply to the Icahn Group, other than the Icahn
Designees in their capacity as members of the Board. 

  

	 	(c)	 Any provision in this Agreement to the contrary notwithstanding, if at any time after the Distribution
Effective Date, the Icahn Group, together with any Icahn Affiliates (as defined below), ceases collectively to beneficially own (for all purposes in this Agreement, the terms “beneficially own” and “beneficial ownership” shall
have the meaning ascribed to such terms as defined in Rule 13d-3 (as in effect from time to time) promulgated by the SEC under the Exchange Act), an aggregate Net Long Position (x) in at least six percent
(6%) of the total outstanding common shares of the Company (“Common Shares”) as of the Distribution Effective Date (as adjusted for any stock dividends, combinations, splits, recapitalizations and similar type events), (1) one of
the Icahn Designees (or, if applicable, his or her Replacement Designee) shall, and the Icahn Group shall cause such Icahn Designee to, promptly tender his or her resignation from the Board and any committee of the Board on which he or she then sits
and (2) the Icahn Group shall not have the right to replace such Icahn Designee; or (y) in at least three percent (3%) of the total outstanding Common Shares as of the Distribution Effective Date (as adjusted for any stock dividends,
combinations, splits, recapitalizations and similar type events), (1) each of the Icahn Designees (or, if applicable, his or her Replacement Designee) shall, and the Icahn Group shall cause such Icahn Designee to, promptly tender his or her
resignation from the Board 

  
 4 

	 	
and any committee of the Board on which he or she then sits and (2) the Icahn Group shall not have the right to replace such Icahn Designee(s). For clarity, “Common Shares” will
include the shares of the entity resulting from the amalgamation of the Company expected to be effected in connection with the B+L Distribution for which the Common Shares are exchanged pursuant to such amalgamation. 

The Icahn Group, upon request, shall keep the Company regularly apprised of the Net Long Position of the Icahn Group and the Icahn Affiliates
to the extent that such position differs from the ownership positions publicly reported on the Icahn Schedule 13D and amendments thereto. 

For purposes of this Agreement: the term “Net Long Position” shall mean: such Common Shares beneficially owned, directly or
indirectly, that constitute such person’s net long position as defined in Rule 14e-4 under the Exchange Act mutatis mutandis, provided that “Net Long Position” shall not include any
shares as to which such person does not have the right to vote or direct the vote, or as to which such person has entered into a derivative or other agreement, arrangement or understanding that hedges or transfers, in whole or in part, directly or
indirectly, any of the economic consequences of ownership of such shares; and the terms “person” or “persons” shall mean any individual, corporation (including
not-for-profit), general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other
entity of any kind or nature. 
 Each of the Icahn Designees shall, prior to his or her appointment to the Board (including any Replacement
Designee), and each member of the Icahn Group shall cause each of the Icahn Designees (including any Replacement Designee) to, execute an irrevocable resignation in the form attached to this Agreement as Exhibit A. 

 

	 	(d)	 So long as the Icahn Group, together with the Icahn Affiliates, beneficially owns an aggregate Net Long
Position in at least six percent (6%) of the total outstanding Common Shares as of the Distribution Effective Date (as adjusted for any stock dividends, combinations, splits, recapitalizations or similar type events), the Company shall not
adopt a Rights Plan with an “Acquiring Person” beneficial ownership threshold below 20.0% of the then-outstanding Common Shares, unless (x) such Rights Plan provides that, if such Rights Plan is not ratified by the Company’s
stockholders within 105 days of such Rights Plan being adopted, such Rights Plan shall automatically expire and (y) the “Acquiring Person” definition of such Rights Plan exempts the Icahn Group up to a beneficial ownership of 19.95%
of the then-outstanding Common Shares. The term “Rights Plan” shall mean any plan or arrangement of the sort commonly referred to as a “rights plan” or “stockholder rights plan” or “shareholder rights
plan” or “poison pill” that is designed to increase the cost to a potential acquirer of exceeding the applicable ownership thresholds through the issuance of new rights, common stock or preferred shares (or any other security or
device that may be issued to stockholders of the Company, other than ratably to all stockholders of the Company) that carry severe redemption provisions, favorable purchase provisions or otherwise, and any related rights agreement.

  

	2.	 Additional Agreements. 

 

	 	(a)	 Unless the Company or the Board has breached any material provision of this Agreement and failed to cure such
breach within five (5) business days following the receipt of written notice from the Icahn Group specifying any such breach, solely in connection with the First Annual Meeting, each member of the Icahn Group shall (1) cause, in the case
of all Voting 

  
 5 

	 	
Securities owned of record, and (2) instruct and cause the record owner, in the case of all shares of Voting Securities beneficially owned but not owned of record, directly or indirectly, by
it, or by any Icahn Affiliate, in each case as of the record date of the First Annual Meeting, in each case that are entitled to vote at the First Annual Meeting, to be present for quorum purposes and to be voted, at the First Annual Meeting or at
any adjournment or postponement thereof, (A) for each nominee on the First BLCO Slate, (B) against any nominees that are not nominated by the Board for election at the First Annual Meeting, (C) against any stockholder proposal to
increase the size of the Board and (D) in favor of the ratification of the Company’s auditors. Except as provided in the foregoing sentence and in Section 2(b), the Icahn Group shall not be restricted from voting “For”,
“Against” or “Abstaining” from any other proposals at any annual or special meeting. 

  

	 	(b)	 Unless the Company or the Board has breached any material provision of this Agreement and failed to cure such
breach within five (5) business days following the receipt of written notice from the Icahn Group specifying any such breach, that for any annual general meeting or special meeting of stockholders subsequent to the First Annual Meeting, if the
Board has agreed to nominate the Icahn Designees then serving on the Board for election at such annual general meeting or special meeting and the Icahn Designees have consented to be nominated at such annual general meeting or special meeting, each
member of the Icahn Group shall (1) cause, in the case of all Voting Securities owned of record, and (2) instruct and cause the record owner, in the case of all shares of Voting Securities beneficially owned but not owned of record,
directly or indirectly, by it, or by any Icahn Affiliate, in each case as of the record date of the applicable annual general meeting or special meeting, in each case that are entitled to vote at such annual general meeting or special meeting, to be
present for quorum purposes and to be voted at such annual general meeting or special meeting or at any adjournment or postponement thereof, (A) for each director nominated by the Board for election at such annual general meeting,
(B) against any (i) stockholder proposal to increase the size of the Board and (ii) nominees that are not nominated by the Board for election at such annual general meeting or special meeting, and (C) in favor of the ratification
of the Company’s auditors. Except as provided in the foregoing sentence, the Icahn Group shall not be restricted from voting “For”, “Against” or “Abstaining” from any other proposals at any annual general meeting
or special meeting following the First Annual Meeting. 

 As used in this Agreement, the term “Voting
Securities” shall mean the Common Shares that such person has the right to vote or has the right to direct the vote. For purposes of this Section 2, no person shall be, or be deemed to be, the “beneficial owner” of, or to
“beneficially own,” any securities beneficially owned by any director of the Company to the extent such securities were acquired directly from the Company by such director as or pursuant to director compensation for serving as a director
of the Company. For purposes of this Agreement, (A) the term “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act, and the term
“Icahn Affiliate” shall mean such Affiliates that are controlled by the members of the Icahn Group, and (B) the term “Associate” shall mean (A) any trust or other estate in which such person has a
substantial beneficial interest or as to which such person serves as trustee or in a similar fiduciary capacity, and (B) any relative or spouse of such person, or any relative of such spouse, who has the same home as such person or who is a
director or officer of such person or of any of its parents or subsidiaries. 

  
 6 

	3.	 Icahn Group Restrictions 

 

	 	(a)	 From and after the date that the Icahn Designees are seated as members of the Board, until the later of (i)(x)
the end of the First Annual Meeting and (y) such date as no Icahn Designee is on the Board and the Icahn Group has no right to designate a Replacement Designee (including if the Icahn Group has irrevocably waived such right in writing), and
(ii) solely with respect to Section 3(a)(i)(x), the Butterfly Date (as hereafter defined) (the “Standstill Period”), so long as the Company has not breached any material provision of this Agreement and
failed to cure such breach within five (5) business days following the receipt of written notice from the Icahn Group specifying any such breach, no member of the Icahn Group shall, directly or indirectly, and each member of the Icahn Group
shall cause each of the Icahn Affiliates and its Associates not to, directly or indirectly (it being understood that the foregoing shall not restrict the Icahn Designees from discussing the matters set forth below with other members of the Board):

  

	 	(i)	 acquire, offer or propose to acquire any voting securities (or beneficial ownership thereof), or rights or
options to acquire any voting securities (or beneficial ownership thereof) of the Company if after any such case, immediately after the taking of such action the Icahn Group, together with its respective Icahn Affiliates, would in the aggregate,
beneficially own more than 19.95% of the then outstanding Common Shares (excluding, for the avoidance of doubt, any cash-settled swaps or other cash-settled instruments); provided that: (x) if, solely as a result of their acquisition of Common
Shares or securities or other instruments convertible into Common Shares, the Icahn Group, together with its respective Icahn Affiliates and its Associates, become the beneficial owners of more than 9.95% of the then outstanding Common Shares
(excluding, for the avoidance of doubt, any cash-settled swaps or other cash-settled instruments), then neither the Icahn Group nor the Icahn Affiliates nor its Associates shall sell any Common Shares or securities or other instruments convertible
into Common Shares (but excluding, for the avoidance of doubt, any swaps or other instruments that do not allow for settlement in property other than cash) following the Distribution Effective Date and prior to the Butterfly Date without first
obtaining a supplemental tax ruling from the Canada Revenue Agency (“CRA”) or an opinion of a nationally recognized accounting firm or law firm that is in form and substance satisfactory to the Company, acting reasonably, that such
sale will not cause the B+L Distribution to be taxed in a manner inconsistent with that provided for in the tax ruling issued by the CRA in connection with the B+L Distribution; and (y) the term “Butterfly Date” shall mean the
date that is the earlier of (A) eighteen (18) months after the Distribution Effective Date and (B) the date the Company delivers written notice to the Icahn Group in accordance with Section 12 confirming that BHC is not proceeding
with a Canadian “butterfly” form of spin out with respect to the B+L Distribution; 

  

	 	(ii)	 except with respect to the signatories to the Icahn Group’s Schedule 13D filed with the SEC with respect
to the Company (the “Icahn Schedule 13D”), form or join in a partnership, limited partnership, syndicate or a “group” as defined under Section 13(d) of the Exchange Act, with respect to the securities of the Company;

  
 7 

	 	(iii)	 present (or request to present) at any annual general meeting or any special meeting of the Company’s
stockholders, any proposal for consideration for action by stockholders or engage in any solicitation of proxies or consents or become a “participant” in a “solicitation” (as such terms are defined in Regulation 14A under the
Exchange Act) of proxies or consents (including, without limitation, any solicitation of consents that seeks to call a special meeting of stockholders) or, except as provided in this Agreement, otherwise publicly propose (or publicly request to
propose) any nominee for election to the Board or seek representation on the Board or the removal of any member of the Board; 

  

	 	(iv)	 grant any proxy, consent or other authority to vote with respect to any matters (other than to the named
proxies included in the Company’s proxy card for any annual general meeting or special meeting of stockholders) or deposit any Voting Securities in a voting trust or subject them to a voting agreement or other arrangement of similar effect
(excluding customary brokerage accounts, margin accounts, prime brokerage accounts and the like), in each case, except as provided in Sections 2(a) or (b); 

  

	 	(v)	 call or seek to call any special meeting of the Company or action by consent resolutions;

  

	 	(vi)	 institute, solicit, assist or join, as a party, any litigation, arbitration or other proceeding against or
involving the Company; 

  

	 	(vii)	 separately or in conjunction with any other person in which it is or proposes to be either a principal, partner
or financing source or is acting or proposes to act as broker or agent for compensation, submit a proposal for or offer of (with or without conditions), any Extraordinary Transaction (as defined below); provided that the Icahn Group shall be
permitted to sell or tender their Common Shares, and otherwise receive consideration, pursuant to any Extraordinary Transaction; and provided further that (A) if a third party (other than the Icahn Group or an Icahn Affiliate) commences a
tender offer or exchange offer for all of the outstanding Common Shares that is not rejected by the Board in its Recommendation Statement on Schedule 14D-9, then the Icahn Group shall similarly be permitted to
make an offer for the Company or commence a tender offer or exchange offer for all of the outstanding Common Shares at the same or higher consideration per share, provided that the foregoing (y) will not relieve the Icahn Group of its
obligations under the Confidentiality Agreement and (z) will not be deemed to require the Company to make any public disclosures and (B) the Company may waive the restrictions in this Section 3(a)(vii) with the approval of the Board.
“Extraordinary Transaction” means, collectively, any of the following involving the Company or any of its subsidiaries or its or their securities or all or substantially all of the assets or businesses of the Company and its subsidiaries:
any tender offer or exchange offer, merger, acquisition, business combination, reorganization, restructuring, recapitalization, sale or acquisition of material assets, or liquidation or dissolution; provided that Extraordinary Transaction shall not
include, and neither this Section 3(a) nor any other term of this Agreement, shall restrict the Icahn Group from commencing and consummating a tender offer pursuant to applicable Canadian laws and regulations to acquire additional Common
Shares, so long as upon consummation of such tender offer(s) the Icahn Group would comply with Section 3(a)(i); provided, further that this Section 3(a)(vi) shall not prevent an Icahn Designee acting in his or her
capacity as a director of the Company from raising such matter privately at the Board; 

  
 8 

	 	(viii)	 seek, or encourage any person, to submit nominations in furtherance of a “contested solicitation” for
the election or removal of directors with respect to the Company or, except as expressly provided in this Agreement, seek, encourage or take any other action with respect to the election or removal of any directors; 

 

	 	(ix)	 make any public communication in opposition to (A) any merger, acquisition, amalgamation,
recapitalization, restructuring, disposition, distribution, spin-off, asset sale, joint venture or other business combination (including the B+L Distribution) or (B) any financing transaction, in each
case involving the Company; 

  

	 	(x)	 seek to advise, encourage, support or influence any person with respect to the voting or disposition of any
securities of the Company at any annual general meeting or special meeting of stockholders, except in accordance with Section 2(a) or (b); 

  

	 	(xi)	 publicly disclose any intention, plan or arrangement inconsistent with any provision of this Section 3; or

  

	 	(xii)	 publicly encourage or support any other person to take any of the actions described in this Section 3 that
the Icahn Group is restricted from doing. 

  

	 	(b)	 Subject to applicable law, from the date of this Agreement until the end of the Standstill Period, (i) so
long as the Company has not breached any material provision of this Agreement and failed to cure such breach within five (5) business days following the receipt of written notice from the Icahn Group specifying any such breach, neither a member
of the Icahn Group nor any of the Icahn Affiliates or its Associates (including such persons’ officers, directors and persons holding substantially similar positions however titled) shall make, or cause to be made, by press release or similar
public statement, including to the press or media (including social media), or in an SEC or other public filing, any statement or announcement that disparages (as distinct from objective statements reflecting business criticism) the Company or the
Company’s respective current or former officers or directors and (ii) so long as the Icahn Group has not breached any material provision of this Agreement and failed to cure such breach within five (5) business days following the
receipt of written notice from the Company specifying any such breach, neither the Company nor any of its Affiliates or Associates (including such persons’ officers, directors and persons holding substantially similar positions however titled)
shall make, or cause to be made, by press release or similar public statement, including to the press or media (including social media), or in an SEC or other public filing, any statement or announcement that disparages (as distinct from objective
statements reflecting business criticism) any member of the Icahn Group or Icahn Affiliates or any of their respective current or former officers or directors. 

 

	4.	 Public Announcements. The Company acknowledges that the Icahn Group intends to file this Agreement as an
exhibit to the Icahn Group’s Schedule 13D with respect to the Company promptly following the Distribution Effective Date, and the Icahn Group acknowledges that the Company intends to file this Agreement as an exhibit to the Company’s Form S-1/A promptly following the execution of this Agreement. The Icahn Group will not issue a press release. The Company shall have an opportunity to review in advance any Schedule 13D filing made by the Icahn Group
with respect to this Agreement, and the Icahn Group shall have an opportunity to review in advance the relevant portion of the Form S-1/A filing to be made by the Company with respect to this Agreement.

  
 9 

	5.	 Confidentiality Agreement. The Company hereby agrees that, following the appointment of the Icahn
Designees to the Board: (i) the Icahn Designees are permitted to and may provide confidential information subject to and in accordance with the terms of the confidentiality agreement in the form attached to this Agreement as Exhibit B
(the “Confidentiality Agreement”) (which the Icahn Group agrees to execute upon the Icahn Group’s valid exercise of its nomination rights pursuant to Section 1(a)(i) and deliver to the Company and
cause the Icahn Designees to abide by) and (ii) the Company will execute and deliver the Confidentiality Agreement to the Icahn Group substantially contemporaneously with execution and delivery thereof by the other signatories thereto. At any
time an Icahn Designee is a member of the Board, the Board shall not adopt a policy precluding members of the Board from speaking to Mr. Icahn, and the Company confirms that it will advise members of the Board, including the Icahn Designees,
that they may, but are not obligated to, speak to Mr. Icahn (but subject to the Confidentiality Agreement), if they are willing to do so and subject to their fiduciary duties and Company Policies (but may caution them regarding specific
matters, if any, that involve conflicts between the Company and the Icahn Group). 

  

	6.	 Representations and Warranties of All Parties. Each of the parties represents and warrants to the other
party that: (a) such party has all requisite company power and authority to execute and deliver this Agreement and to perform its obligations hereunder; (b) this Agreement has been duly and validly authorized, executed and delivered by it
and is a valid and binding obligation of such party, enforceable against such party in accordance with its terms; and (c) this Agreement will not result in a violation of any terms or conditions of any agreements to which such person is a party
or by which such party may otherwise be bound or of any law, rule, license, regulation, judgment, order or decree governing or affecting such party. 

  

	7.	 Representations and Warranties of Icahn Group. Each member of the Icahn Group jointly represents and
warrants that, as of the date of this Agreement, (a) the Icahn Group collectively beneficially own, an aggregate of 34,721,118 common shares, no par value (excluding, for the avoidance of doubt, any cash-settled swaps or other cash-settled
instruments), of BHC (“BHC Common Shares”) and no Common Shares, (b) except as set forth in the preceding clause (a) and the Icahn Group’s Schedule 13Ds with respect to BHC or the Company or as otherwise disclosed to
the Company, no member of the Icahn Group, individually or in the aggregate with any Icahn Affiliate, has any other beneficial ownership of, or economic exposure to, any BHC Common Shares or Common Shares, nor does it currently have or have any
right to acquire any interest in any other securities of BHC or the Company (or any rights, options or other securities convertible into or exercisable or exchangeable (whether or not convertible, exercisable or exchangeable immediately or only
after the passage of time or the occurrence of a specified event) for such securities or any obligations measured by the price or value of any securities of BHC, the Company or any of their respective controlled Affiliates, including any swaps or
other derivative arrangements designed to produce economic benefits and risks that correspond to the ownership of BHC Common Shares or Common Shares, whether or not any of the foregoing would give rise to beneficial ownership (as determined under
Rule 13d-3 promulgated under the Exchange Act), and whether or not to be settled by delivery of BHC Common Shares or Common Shares, payment of cash or by other consideration, and without regard to any short position under any such contract or
arrangement), and (c) no member of the Icahn Group has any knowledge of any other stockholder of BHC or the Company that intends to submit a notice to the Company to nominate directors at the next Annual Meeting of shareholders of BHC or the
Company. 

  
 10 

	8.	 Representations and Warranties and Covenants of the Company. The Company represents and warrants, that
as of the date of this Agreement, the Company expects that the directors so identified in the Company’s Form S-1 filed with the SEC on January 13, 2022 shall be all of the directors on the Board as
of the completion of the Company’s initial public offering of Common Shares. Further, the Company agrees that if the Company enters into an agreement, arrangement or understanding, or otherwise grants any rights, to any other stockholder of the
Company to avoid a proxy or similar contest with such stockholder at any time during the three (3) months following the date that the Icahn Designees are seated as directors of the Company, then to the extent such agreement, arrangement or
understanding grants any right or rights that are more favorable than those set forth in this Agreement, the Company agrees it shall offer the same such rights to the Icahn Group. 

 

	9.	 Miscellaneous. This Agreement shall terminate and be of no further force or effect upon the earliest of
the occurrence of any of the following events: (a) following the Board’s appointment of the Icahn Designees to the Board pursuant to Section 1(a)(i), (i) no Icahn Designee then serving on the Board and
(ii) the Icahn Group no longer being entitled to designate a Replacement Designee for any Icahn Designee, (b) the expiry of the Election Period without the Icahn Group’s valid exercise of its nomination rights pursuant to
Section 1(a)(i), (c) following the completion of the B+L Distribution, the Icahn Group not collectively beneficially owning an aggregate Net Long Position in at least three percent (3%) of the total outstanding Common
Shares as of the Distribution Effective Date (as adjusted for any stock dividends, combinations, splits, recapitalizations and similar type events), and (d) any breach by the Icahn Group of its covenants and obligations set forth in
Section 1(a)(ii) and Section 3(a) (including any action taken prior to the commencement of the Standstill Period that would be a breach of Section 3(a) if taken during the
Standstill Period). Notwithstanding anything herein to the contrary, Section 3(a)(i) shall survive any such termination through the Butterfly Date. The parties hereto recognize and agree that if for any reason any of the
provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached, immediate and irreparable harm or injury would be caused for which money damages would not be an adequate remedy. Accordingly, each
party agrees that in addition to other remedies the other party shall be entitled to at law or equity, the other party shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement exclusively in the Delaware Court of Chancery or other federal or state courts of the State of Delaware. In the event that any action shall be brought in equity to enforce the provisions of this Agreement, no party shall
allege, and each party hereby waives the defense, that there is an adequate remedy at law. Furthermore, each of the parties hereto (i) consents to submit itself to the personal jurisdiction of the Delaware Court of Chancery or other federal or
state courts of the State of Delaware in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (ii) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or
other request for leave from any such court, (iii) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the Delaware Court of Chancery or the other
federal or state courts of the State of Delaware, and each of the parties irrevocably waives the right to trial by jury, (iv) agrees to waive any bonding requirement under any applicable law, in the case any other party seeks to enforce the
terms by way of equitable relief, and (v) irrevocably consents to service of process by a reputable overnight mail delivery service, signature requested, to the address of such party’s principal place of business or as otherwise provided
by applicable law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN SUCH STATE WITHOUT GIVING
EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE. 

  
 11 

	10.	 No Waiver. Any waiver by any party of a breach of any provision of this Agreement shall not operate as
or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not
be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement. 

  

	11.	 Entire Agreement. This Agreement and the Confidentiality Agreement contain the entire understanding of
the parties with respect to the subject matter hereof and may be amended only by an agreement in writing executed by the parties hereto. 

  

	12.	 Notices. All notices, consents, requests, instructions, approvals and other communications provided for
herein and all legal process in regard hereto shall be in writing and shall be deemed validly given, made or served, if (a) given by telecopy and email, when such telecopy and email is transmitted to the telecopy number set forth below and sent
to the email address set forth below and the appropriate confirmation is received or (b) if given by any other means, when actually received during normal business hours at the address specified in this subsection: 

if to the Company: 

Bausch + Lomb Corporation 

520 Applewood Crescent 

Vaughan, Ontario, Canada L4K 4B4 

Email: [*****] 

Attention: Christina Ackermann, General Counsel 

With copies to (which shall not constitute notice): 

Wachtell, Lipton, Rosen & Katz 

51 West 52 Street 

New York, NY 10019 

Attention: Igor Kirman, [*****] 

  Mark Veblen, [*****] 

  Sabastian Niles, [*****] 

if to the Icahn Group: 

Icahn Capital LP 
 16690 Collins
Avenue, Penthouse Suite 
 Sunny Isles Beach, FL 33160 

Attention: Jesse Lynn, Chief Operating Officer 

Email: [*****] 
  

	13.	 Severability. If at any time subsequent to the date of this Agreement, any provision of this Agreement
shall be held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have no effect upon the legality or
enforceability of any other provision of this Agreement. 

  

	14.	 Counterparts. This Agreement may be executed (including by facsimile or PDF) in two or more counterparts
which together shall constitute a single agreement. 

  
 12 

	15.	 Successors and Assigns. This Agreement shall not be assignable by any of the parties to this Agreement.
This Agreement, however, shall be binding on successors of the parties hereto. 

  

	16.	 No Third Party Beneficiaries. This Agreement is solely for the benefit of the parties hereto and is not
enforceable by any other persons. 

  

	17.	 Fees and Expenses. Neither the Company, on the one hand, nor the Icahn Group, on the other hand, will be
responsible for any fees or expenses of the other in connection with this Agreement. 

  

	18.	 Interpretation and Construction. Each of the parties hereto acknowledges that it has been represented by
counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel. Each party and its counsel cooperated and participated in the
drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by
reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby
expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or preparation. The section headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Unless context otherwise requires, references herein to Exhibits, Sections or Schedules mean the Exhibits, Sections or Schedules attached to this
Agreement. The term “including” shall be deemed to mean “including without limitation” in all instances. In all instances, the term “or” shall not be deemed to be exclusive. For all purposes of this Agreement, and any
exhibit, appendix or attachment hereto (including, for the avoidance of doubt, Exhibit A), the Icahn Group and its Icahn Affiliates shall in no event be deemed to beneficially own less than six percent (6%), or three percent (3%), as applicable, of
the outstanding Common Shares unless the Icahn Group’s crossing of any such threshold is the result of sales of Common Shares or transactions described in Rule 14e-4(a)(1) of the Exchange Act (but
excluding, for the avoidance of doubt, any cash-settled swaps or other cash-settled instruments) by, or on behalf of, the Icahn Group or its Icahn Affiliates (i.e., issuances of Common Shares, or similar actions, by the Company shall have no effect
on the deemed beneficial ownership of Common Shares by the Icahn Group and its Icahn Affiliates for purposes of this this Agreement, or any exhibit, appendix or attachment hereto (including, for the avoidance of doubt, Exhibit A)).

 [Signature Pages Follow] 

  
 13 

 IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, or caused
the same to be executed by its duly authorized representative as of the date first above written. 
  

			
	BAUSCH + LOMB CORPORATION
		
	By:	 	 /s/ Christina M. Ackermann

	Name:	 	Christina M. Ackermann
	Title:	 	 Executive Vice President and General Counsel

  
 [Signature Page to
Director Appointment and Nomination Agreement between 
 Bausch + Lomb Corporation and the Icahn Group] 

 
			
	ICAHN GROUP
	
	 /s/ Carl C. Icahn

	Carl C. Icahn
	
	ICAHN PARTNERS LP
		
	By:	 	 /s/ Jesse Lynn

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN PARTNERS MASTER FUND LP
		
	By:	 	 /s/ Jesse Lynn

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN ENTERPRISES G.P. INC.
		
	By:	 	 /s/ Ted Papapostolou

	Name:	 	Ted Papapostolou
	Title:	 	Chief Financial Officer

  

  
 [Signature Page to
Director Appointment and Nomination Agreement between 
 Bausch + Lomb Corporation and the Icahn Group] 

 
			
	ICAHN ENTERPRISES HOLDINGS L.P.
	
	By: Icahn Enterprises G.P. Inc., its general partner
		
	By:	 	 /s/ Ted Papapostolou

	Name:	 	Ted Papapostolou
	Title:	 	Chief Financial Officer
	
	IPH GP LLC
		
	By:	 	 /s/ Jesse Lynn

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN CAPITAL LP
		
	By:	 	 /s/ Jesse Lynn

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN ONSHORE LP
		
	By:	 	 /s/ Jesse Lynn

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN OFFSHORE LP
		
	By:	 	 /s/ Jesse Lyn

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	BECKTON CORP
		
	By:	 	 /s/ Jesse Lyn

	Name:	 	Jesse Lynn
	Title:	 	Vice President

  

  
 [Signature Page to
Director Appointment and Nomination Agreement between 
 Bausch + Lomb Corporation and the Icahn Group] 

 SCHEDULE A 

CARL C. ICAHN 
 ICAHN PARTNERS LP 

ICAHN PARTNERS MASTER FUND LP 
 ICAHN ENTERPRISES G.P. INC. 

ICAHN ENTERPRISES HOLDINGS L.P. 
 IPH GP LLC 

ICAHN CAPITAL LP 
 ICAHN ONSHORE LP 

ICAHN OFFSHORE LP 
 BECKTON CORP. 

 

 EXHIBIT A 

[FORM OF RESIGNATION] 
 [DATE] 

Board of Directors 
 Bausch + Lomb Corporation 

520 Applewood Crescent 
 Vaughan, Ontario, Canada L4K 4B4 

 

	Re:	 Resignation 

Ladies and Gentlemen: 
 This irrevocable
resignation is delivered pursuant to that certain Director Appointment and Nomination Agreement, dated as of April [__], 2022 (the “Agreement”) among Bausch + Lomb Corporation and the Icahn Group. Capitalized terms used herein but not
defined shall have the meaning set forth in the Agreement. 
 Pursuant to Section 1(c) of the Agreement, effective only upon, and
subject to, such time as the Icahn Group (together with the Icahn Affiliates) ceases collectively to beneficially own (as defined in Rule 13d-3 (as in effect from time to time) promulgated by the SEC under the
Exchange Act) an aggregate Net Long Position in at least six percent (6%) of the total outstanding Common Shares as of the Distribution Effective Date, I hereby irrevocably resign from my position as a director of the Company and from any and all
committees of the Board on which I serve; provided, however, that if this resignation is tendered pursuant to Section 1(c) of the Agreement, this resignation shall not be effective if any other resignation of an Icahn Designee is
tendered and accepted pursuant to Section 1(c) of the Agreement (and the Icahn Group shall determine in its sole discretion which resignation of the Icahn Designees shall be effective) unless and until the Icahn Group (together with the Icahn
Affiliates) ceases collectively to beneficially own (as defined in Rule 13d-3 (as in effect from time to time) promulgated by the SEC under the Exchange Act) an aggregate Net Long Position in at least three
percent (3%) of the total outstanding Common Shares as of the Distribution Effective Date. 
  

	
	Sincerely,
	  

	
	Name:

  
 B-1 

 EXHIBIT B 

[CONFIDENTIALITY AGREEMENT] 

  
 B-1 

 CONFIDENTIALITY AGREEMENT 

BAUSCH + LOMB CORPORATION 
 [DATE] 

To: Each of the persons or entities listed on Schedule A (the “Icahn Group” or “you”) 

Ladies and Gentlemen: 
 This letter agreement
shall become effective upon the appointment of any Icahn Designee to the Board of Directors (the “Board”) of Bausch + Lomb Corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall
have the meanings given to such terms in the Director Appointment and Nomination Agreement (the “Nomination Agreement”), dated as of April [__], 2022, among the Company and the Icahn Group. The Company understands and agrees that,
subject to the terms of, and in accordance with, this letter agreement, an Icahn Designee may, if and to the extent he or she desires to do so, disclose information he or she obtains while serving as a member of the Board to you and your
Representatives (as hereinafter defined), and may discuss such information with any and all such persons, subject to the terms and conditions of this Agreement, and that other members of the Board may similarly disclose information to you. As a
result, you may receive certain non-public information regarding the Company. You acknowledge that this information is proprietary to the Company and may include trade secrets or other business information the
disclosure of which could harm the Company. In consideration for, and as a condition of, the information being furnished to you and your agents, representatives, attorneys, advisors, directors, officers or employees, subject to the restrictions in
paragraph 2 (collectively, the “Representatives”), you agree to treat any and all information concerning or relating to the Company or any of its subsidiaries or current or former affiliates that is furnished to you or your
Representatives (regardless of the manner in which it is furnished, including in written or electronic format or orally, gathered by visual inspection or otherwise) by any Icahn Designee, or by or on behalf of the Company or any Company
Representative (as defined below), including discussions or matters considered in meetings of the Board or Board committees, together with any notes, analyses, reports, models, compilations, studies, interpretations, documents, records or extracts
thereof containing, referring, relating to, based upon or derived from such information, in whole or in part (collectively, “Evaluation Material”), in accordance with the provisions of this letter agreement, and to take or abstain
from taking the other actions hereinafter set forth. 
  

	1.	 The term “Evaluation Material” does not include information that (i) is or has become generally
available to the public other than as a result of a direct or indirect disclosure by you or your Representatives in violation of this letter agreement or any other obligation of confidentiality, (ii) was within your or any of your
Representatives’ possession on a non-confidential basis prior to its being furnished to you by any Icahn Designee, or by or on behalf of the Company or its agents, representatives, attorneys, advisors,
directors (other than the Icahn Designees), officers or employees (collectively, the “Company Representatives”), or (iii) is received from a source other than any Icahn Designee, the Company or any of the Company
Representatives; provided, that in the case of (ii) or (iii) above, the source of such information was not believed by you, after reasonable inquiry, to be bound by a confidentiality agreement with or other contractual, legal or
fiduciary obligation of confidentiality to the Company or any other person with respect to such information at the time the information was disclosed to you. 

  

	2.	 You and your Representatives will, and you will cause your Representatives to, (a) keep the Evaluation
Material strictly confidential and (b) not disclose any of the Evaluation Material in any manner whatsoever without the prior written consent of the Company; provided, however, that you may privately disclose any of such information:
(A) to your Representatives (i) who need to know 

  
 B-2 

	 	
such information for the purpose of advising you on your investment in the Company and (ii) who are informed by you of the confidential nature of such information and agree to be bound by
the terms of this Agreement as if they were a party hereto; provided, further, that you will be responsible for any violation of this letter agreement by your Representatives as if they were parties to this letter agreement; and (B) to
the Company and the Company Representatives. It is understood and agreed that no Icahn Designee shall disclose to you or your Representatives any Legal Advice (as defined below) that may be included in the Evaluation Material with respect to which
such disclosure would constitute waiver of the Company’s attorney client privilege or attorney work product privilege. “Legal Advice” as used in this letter agreement shall be solely and exclusively limited to the advice
provided by legal counsel and shall not include factual information or the formulation or analysis of business strategy that is not protected by the attorney-client or attorney work product privilege. 

 

	3.	 In the event that you or any of your Representatives are required by applicable subpoena, legal process or
other legal requirement to disclose any of the Evaluation Material, you will (a) promptly notify (except where such notice would be legally prohibited) the Company in writing by email, facsimile and certified mail so that the Company may seek a
protective order or other appropriate remedy (and if the Company seeks such an order, you will provide such cooperation as the Company shall reasonably request), at its cost and expense and (b) produce or disclose only that portion of the
Evaluation Material which your outside legal counsel of national standing advises you in writing is legally required to be so produced or disclosed and you inform the recipient of such Evaluation Material of the existence of this letter agreement
and the confidential nature of such Evaluation Material. In no event will you or any of your Representatives oppose action by the Company to obtain a protective order or other relief to prevent the disclosure of the Evaluation Material or to obtain
reliable assurance that confidential treatment will be afforded the Evaluation Material. For the avoidance of doubt, it is understood that there shall be no “legal requirement” requiring you to disclose any Evaluation Material solely by
virtue of the fact that, absent such disclosure, you would be prohibited from purchasing, selling, or engaging in derivative or other voluntary transactions with respect to the Common Shares of the Company or otherwise proposing or making an offer
to do any of the foregoing, or you would be unable to file any proxy or other solicitation materials in compliance with Section 14(a) of the Exchange Act or the rules promulgated thereunder. 

 

	4.	 You acknowledge that (a) none of the Company or any of the Company Representatives makes any
representation or warranty, express or implied, as to the accuracy or completeness of any Evaluation Material, and (b) none of the Company or any of the Company Representatives shall have any liability to you or to any of your Representatives
relating to or resulting from the use of the Evaluation Material or any errors therein or omissions therefrom. You and your Representatives (or anyone acting on your or their behalf) shall not directly or indirectly initiate contact or communication
with any executive or employee of the Company other than the Chairman of the Board, Chief Executive Officer, Chief Financial Officer, General Counsel, or such other persons approved by the foregoing or the Board concerning Evaluation Material, or to
seek any information in connection therewith from any such person other than the foregoing, without the prior consent of the Company; provided, however, the restriction in this sentence shall not in any way apply to any Icahn Designee acting
in his or her capacity as a Board member (nor shall it apply to any other Board members). 

  

	5.	 All Evaluation Material shall remain the property of the Company. Neither you nor any of your Representatives
shall by virtue of any disclosure of or your use of any Evaluation Material acquire any rights with respect thereto, all of which rights (including all intellectual property rights) shall remain exclusively with the Company. At any time after the
date on which no Icahn Designee is a 

  
 B-3 

	 	
director of the Company, upon the request of the Company for any reason, you will promptly return to the Company or destroy all hard copies of the Evaluation Material and use reasonable best
efforts to permanently erase or delete all electronic copies of the Evaluation Material in your or any of your Representatives’ possession or control (and, upon the request of the Company, shall promptly certify to the Company that such
Evaluation Material has been erased or deleted, as the case may be). Notwithstanding the foregoing, the obligation to return or destroy Evaluation Material shall not cover information (i) that is maintained on routine computer system backup
tapes, disks or other backup storage devices as long as such backed-up information is not used, disclosed, or otherwise recovered from such backup devices or (ii) retained on a confidential basis solely
to the extent required to comply with applicable law and/or any internal record retention requirements; provided that such materials referenced in this sentence shall remain subject to the terms of this Agreement applicable to Evaluation Material,
and you and your Representatives will continue to be bound by the obligations contained herein for as long as any such materials are retained by you or your Representatives. 

 

	6.	 You acknowledge, and will advise your Representatives, that the Evaluation Material may constitute material non-public information under applicable federal, state or provincial securities laws, and you agree that you shall not, and you shall use reasonable best efforts to ensure that your Representatives do not, trade or
engage in any derivative or other transaction on the basis of such information in violation of such laws. 

  

	7.	 You hereby represent and warrant to the Company that (i) you have all requisite company power and
authority to execute and deliver this letter agreement and to perform your obligations hereunder, (ii) this letter agreement has been duly authorized, executed and delivered by you, and is a valid and binding obligation, enforceable against you
in accordance with its terms, (iii) this letter agreement will not result in a violation of any terms or conditions of any agreements to which you are a party or by which you may otherwise be bound or of any law, rule, license, regulation,
judgment, order or decree governing or affecting you, and (iv) your entry into this letter agreement does not require approval by any owners or holders of any equity or other interest in you (except as has already been obtained).

  

	8.	 Any waiver by the Company of a breach of any provision of this letter agreement shall not operate as or be
construed to be a waiver of any other breach of such provision or of any breach of any other provision of this letter agreement. The failure of the Company to insist upon strict adherence to any term of this letter agreement on one or more occasions
shall not be considered a waiver or deprive the Company of the right thereafter to insist upon strict adherence to that term or any other term of this letter agreement. 

 

	9.	 You acknowledge and agree that the value of the Evaluation Material to the Company is unique and substantial,
but may be impractical or difficult to assess in monetary terms. You further acknowledge and agree that in the event of an actual or threatened violation of this letter agreement, immediate and irreparable harm or injury would be caused for which
money damages would not be an adequate remedy. Accordingly, you acknowledge and agree that, in addition to any and all other remedies which may be available to the Company at law or equity, the Company shall be entitled to an injunction or
injunctions to prevent breaches of this letter agreement and to enforce specifically the terms and provisions of this letter agreement exclusively in the Delaware Court of Chancery or other federal or state courts of the State of Delaware. In the
event that any action shall be brought in equity to enforce the provisions of this letter agreement, you shall not allege, and you hereby waive the defense, that there is an adequate remedy at law. 

  
 B-4 

	10.	 Each of the parties (a) consents to submit itself to the personal jurisdiction of the Delaware Court of
Chancery or other federal or state courts of the State of Delaware in the event any dispute arises out of this letter agreement or the transactions contemplated by this letter agreement, (b) agrees that it shall not attempt to deny or defeat
such personal jurisdiction by motion or other request for leave from any such court, (c) agrees that it shall not bring any action relating to this letter agreement or the transactions contemplated by this letter agreement in any court other
than the Delaware Court of Chancery or other federal or state courts of the State of Delaware, and each of the parties irrevocably waives the right to trial by jury, (d) agrees to waive any bonding requirement under any applicable law, in the
case any other party seeks to enforce the terms by way of equitable relief, and (e) irrevocably consents to service of process by a reputable overnight delivery service, signature requested, to the address of such party’s principal place
of business or as otherwise provided by applicable law. THIS LETTER AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED
WHOLLY WITHIN SUCH STATE WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE. 

  

	11.	 This letter agreement and the Nomination Agreement contain the entire understanding of the parties with respect
to the subject matter hereof and thereof and supersedes all prior or contemporaneous agreements or understandings, whether written or oral. This letter agreement may be amended only by an agreement in writing executed by the parties hereto.

  

	12.	 All notices, consents, requests, instructions, approvals and other communications provided for in this letter
agreement and all legal process in regard to this letter agreement shall be in writing and shall be deemed validly given, made or served, if (a) given by telecopy and email, when such telecopy is transmitted to the telecopy number set forth
below and sent to the email address set forth below and the appropriate confirmation is received or (b) if given by any other means, when actually received during normal business hours at the address specified in this subsection:

 if to the Company: 

Bausch + Lomb Corporation 
 520
Applewood Crescent 
 Vaughan, Ontario, Canada L4K 4B4 

Email: [*****] 
 Attention:
Christina Ackermann, General Counsel 
 With copies to (which shall not constitute notice): 

Wachtell, Lipton, Rosen & Katz 

51 West 52 Street 
 New York, NY
10019 
 Attention: Igor Kirman, [*****] 

  Mark Veblen, [*****] 

  Sabastian Niles, [*****] 

  
 B-5 

 if to the Icahn Group: 

Icahn Capital LP 
 16690 Collins
Avenue, Penthouse Suite 
 Sunny Isles Beach, FL 33160 

Attention: Jesse Lynn, Chief Operating Officer 

Email: [*****] 
  

	13.	 If at any time subsequent to the date hereof, any provision of this letter agreement shall be held by any court
of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have no effect upon the legality or enforceability of any other provision
of this letter agreement. 

  

	14.	 This letter agreement may be executed (including by facsimile or PDF) in two or more counterparts which
together shall constitute a single agreement. 

  

	15.	 This letter agreement and the rights and obligations herein may not be assigned or otherwise transferred, in
whole or in part, by you without the express written consent of the Company. This letter agreement, however, shall be binding on successors of the parties to this letter agreement. 

 

	16.	 The Icahn Group shall cause any Replacement Designee appointed to the Board pursuant to the Nomination
Agreement to execute a copy of this letter agreement. 

  

	17.	 This letter agreement shall expire two (2) years from the date on which no Icahn Designee remains a
director of the Company; except that you shall maintain in accordance with the confidentiality obligations set forth herein any Evaluation Material constituting trade secrets for such longer time as such information constitutes a trade secret of the
Company as defined under 18 U.S.C. § 1839(3) and (ii) retained pursuant to Section 5. 

  

	18.	 No licenses or rights under any patent, copyright, trademark, or trade secret are granted or are to be implied
by this letter agreement. 

  

	19.	 Each of the parties acknowledges that it has been represented by counsel of its choice throughout all
negotiations that have preceded the execution of this letter agreement, and that it has executed the same with the advice of said counsel. Each party and its counsel cooperated and participated in the drafting and preparation of this agreement and
the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation.
Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties, and
any controversy over interpretations of this agreement shall be decided without regards to events of drafting or preparation. The term “including” shall in all instances be deemed to mean “including without limitation.” In all
instances, the term “or” shall not be deemed to be exclusive. 

 [Signature Pages Follow] 

  
 B-6 

 Please confirm your agreement with the foregoing by signing and returning one copy of this letter agreement
to the undersigned, whereupon this letter agreement shall become a binding agreement between you and the Company. 
  

			
	Very truly yours,
	
	BAUSCH + LOMB CORPORATION
		
	By:	 	  

	Name:	 	
	Title:

 Accepted and agreed as of the date first written above: 

 

			
	
	 CARL C. ICAHN

	
	  

	Carl C. Icahn
	
	 ICAHN PARTNERS LP

		
	 By:
	 	  

	Name:	 	 Jesse Lynn

	 Title:
	 	 Chief Operating Officer

 [Signature Page to Confidentiality Agreement between Bausch + Lomb Corporation and the Icahn Group] 

 
			
	ICAHN PARTNERS MASTER FUND LP
		
	By:	 	  

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN ENTERPRISES G.P. INC.
		
	By:	 	  

	Name:	 	Ted Papapostolou
	Title:	 	Chief Financial Officer
	
	ICAHN ENTERPRISES HOLDINGS L.P.
	
	By: Icahn Enterprises G.P. Inc., its general partner
		
	By:	 	  

	Name:	 	Ted Papapostolou
	Title:	 	Chief Financial Officer
	
	IPH GP LLC
		
	By:	 	  

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN CAPITAL LP
		
	By:	 	  

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	ICAHN ONSHORE LP
		
	By:	 	  

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer

 [Signature Page to Confidentiality Agreement between Bausch + Lomb Corporation and the Icahn Group] 

 
			
	ICAHN OFFSHORE LP
		
	By:	 	  

	Name:	 	Jesse Lynn
	Title:	 	Chief Operating Officer
	
	BECKTON CORP
		
	By:	 	  

	Name:	 	Jesse Lynn
	Title:	 	Vice President

 [Signature Page to Confidentiality Agreement between Bausch + Lomb Corporation and the Icahn Group] 

 SCHEDULE A 

Beckton Corp. 
 Icahn Capital LP 

Icahn Enterprises Holdings L.P. 
 Icahn Enterprises G.P. Inc.

 Icahn Offshore LP 
 Icahn Onshore LP 

Icahn Partners LP 
 Icahn Partners Master Fund LP 

IPH GP LLC 
 Icahn Capital LP 

Carl C. Icahn 

 ANNEX 1 

Tax Criteria 
 From and after the
Distribution Effective Date, the Icahn Group shall not be permitted to designate any individual as a director of the Company if: (x) such individual, at the time of such designation, is also a member of the board of directors of BHC; and
(y) immediately following such designation, more than two (2) individuals are members of the boards of directors of both BHC and the Company. For example, if on the date of any such designation, Brett Icahn and Steven Miller continue to be
members of the board of directors of BHC, then: (x) if no other individuals are members of the boards of directors of both BHC and the Company, then both Brett Icahn and Steven Miller would be permitted to join the board of directors of the
Company; (y) if two (2) other individuals are members of the boards of directors of both BHC and the Company, then neither Brett Icahn nor Steven Miller would be permitted to join the board of directors of the Company; and (z) if one
(1) other individual is a member of the boards of directors of both BHC and the Company, then Brett Icahn or Steven Miller (but not both) would be permitted to join the board of directors of the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]